The Future Of CBD, Derived From Hemp, Is Still Under Question
FDA is using regulations as a way to discriminate against dietary supplements in favor of Big Pharma and Big Corporations. The saga continues.
FDA is using regulations as a way to discriminate against dietary supplements in favor of Big Pharma and Big Corporations. The saga continues.
It’s a familiar song, the FDA singing high praise for Epidiolex, a pharmaceutical version of CBD that is less effective than the non-approved whole plant version and costs a ton more. Then there’s the matter of Epidiolex side-effects — everything from elevated liver enzymes and infections to attempts of suicide.
The entourage effect refers to hundreds of natural components within a plant interacting together to produce medicine with superior health benefits. Herbalists have recognized this forever … pharmaceuticals not so much.
Is the era of affordable, effective CBD oil coming to an end? Caught between CBD politics and Big Pharma’s backing of the Federal Drug Administration, the industrial hemp industry, as well as thousands of chronic disease sufferers, fear the worst with the likely approval of GW Pharmaceutical’s Epidiolex.